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Background. In several prospective and retrospective studies, weekly paclitaxel showed promising activity in patients with
angiosarcoma. Patients and Methods. Our study was originally designed as a prospective, phase II multicenter trial for patients
younger than 75, with ECOG performance status 0–2, affected by locally advanced or metastatic angiosarcoma. Patients received
paclitaxel 80mg/m2 intravenously, at days 1, 8, and 15 every 4 weeks, until disease progression or unacceptable toxicity. Primary
endpoint was objective response. Results. Eight patients were enrolled but, due to very slow accrual, the trial was prematurely
stopped and further 10 patients were retrospectively included in the analysis. Out of 17 evaluable patients, 6 patients obtained an
objective response (5 partial, 1 complete), with an objective response rate of 35% (95% confidence interval 17%–59%). Of note, five
responses were obtained in pretreated patients. In the paper, details of overall survival, progression-free survival, and tolerability
are reported. Conclusions. In this small series of patients with locally advanced or metastatic angiosarcoma, weekly paclitaxel was
confirmed to be well tolerated and active even in pretreated patients.
1. Introduction
Angiosarcomas are very rare tumors (incidence < 1/100.000/
year) of vascular or lymphatic origin characterized by a
clinical heterogeneity in terms of presentation and behavior.
This subgroup of sarcomas represent about 1-2% of all soft
tissue tumors and can occur in any anatomic site of the body
but most commonly originate in the skin of head and neck
and in breast area [1].
Although etiology is unknown, several risk factors for
angiosarcoma have been described: previous exposure to
radiation therapy [2, 3], vinyl chloride [4], chronic lym-
phedema [5], and prolonged immunosuppression [6, 7].
Regardless of morphology, angiosarcoma is considered
as a high-grade tumor [8] and constitutes one of the most
aggressive subtypes of soft tissue sarcomas with overall
median survival of<4 years. In our experience even angiosar-
comas histologically classified as low grade can develop
distant metastasis.
Wide surgical resection followed as much as possible
by adjuvant radiation therapy is the mainstay of therapy in
patients with localized disease [9, 10].
As for other soft tissue sarcomas chemotherapy is still
not a standard treatment in adjuvant setting, despite the fact
that angiosarcomas develop distant metastasis in up to 50%
of cases [11, 12].
Doxorubicin-based chemotherapy remains the first-line
standard treatment of metastatic or unresectable angiosar-
coma providing a progression-free survival of 3.7–5.4months
and response rate between 40% and 65% [11].
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Taxanes have been found effective in patients affected
by vascular-derived tumors, such as Kaposi sarcoma [13].
Paclitaxel is potent antiangiogenic drug and, at least in
vitro, exhibits its efficacy on human endothelial cells at low-
dose concentration as well as cytotoxic effect at regular
concentration [14–16].
In this paper we report a retrospective series of 17 patients
with advanced angiosarcoma treatedwithweekly paclitaxel in
4 centers of Italian Sarcoma Group.
2. Patients and Methods
2.1. Patients. The study was originally designed as a prospec-
tive, phase II multicenter trial with the aim of assessing activ-
ity and toxicity of the weekly schedule of paclitaxel. Patients
with histological diagnosis of angiosarcoma, with locally
advanced ormetastatic disease, and not eligible for surgery or
recurrent after previous surgerywere eligible for the inclusion
in the study. Previous chemotherapy was allowed, but it
had to be stopped at least 4 weeks before the inclusion in
the protocol. Main exclusion criteria were age younger than
75, performance status worse than 2 according to Eastern
Cooperative Oncology Group, other malignant diseases in
the previous 5 years (with the exception of nonmelanomatous
skin cancer or carcinoma in situ of the uterine cervix),
and brain metastases or inadequate laboratory values (neu-
trophils < 2000/mm3, platelets < 100000/mm3, hemoglobin
< 10 g/dL, serum creatinine level > 1.5 x upper normal limit
(UNL), sAST or sALT > 1.25xUNL in the absence of liver
metastases or >2.5xUNL in the presence of liver metastases,
and serum bilirubin > 1.25xUNL in the absence of liver
metastases or >1.5xUNL in the presence of liver metastases).
The study protocol was approved by the ethical committees
of all participating institutions, and all patients prospectively
enrolled in the trial provided written informed consent.
2.2. Study Treatment. Patients received paclitaxel 80mg/m2
intravenously (IV), at days 1, 8, and 15 every 4 weeks until
disease progression or unacceptable toxicity. Standard pre-
medication with dexamethasone and H1 (promethazine) and
H2 (ranitidine) receptor antagonists was prescribed by proto-
col, before each administration of paclitaxel. Chemotherapy
could be postponed, at Investigator’s discretion, for up to
14 days for persistent hematological toxicity (neutrophils <
1500/mm3; platelets < 100000/mm3; hemoglobin < 8 g/dL)
or persistent nonhematological toxicities grade ≥2. A 25%
dose reduction (60mg/m2) for paclitaxel was planned in case
of previous grade 4 neutropenia lasting more than 3 days
or in case of previous platelets < 50000/mm3. After disease
progression, there was no predetermined salvage treatment
planned by study protocol; however further chemotherapy
was allowed at Investigators’ discretion.
2.3. Assessment Procedures. Patients were evaluated at base-
line with a complete history and physical examination,
routine hematology and biochemistry, chest X-ray, chest
CT scan, abdominal ultrasound, and CT scan (or magnetic
resonance or ultrasound) for specific sites of disease.
Tumor response was assessed by repeating instrumental
exams every two cycles of chemotherapy, by using RECIST
criteria version 1.0 [17].
Toxicity was codified according to National Cancer Insti-
tute Common Terminology Criteria (version 2.0). During
treatment, routine hematology, biochemistry, and physi-
cal examination were performed every 3 administrations
of paclitaxel, before the next cycle. Hematology was also
repeated before eachweekly administration of chemotherapy.
2.4. Sample Size and Statistical Analysis. Objective response
was the primary endpoint of the trial, and the sample size
of the study was determined according to Gehan’s two-stage
design, based on the requirement of stopping the study at
an early stage if the response rate was below 20%, and of
estimating the response rate with a standard error less than
0.10 [18]. If no objective tumor response was observed among
the first 14 evaluable patients, recruitment of patients would
stop, whilst additional (1, 6, 9, or 11) patients had to be
included if there were responses (1, 2, 3, or more than 3, resp.)
in the first 14 patients.
Median follow-up was calculated according to the reverse
Kaplan-Meier technique [19]. Overall survival (OS) was
calculated from the date of treatment start to the date of death,
or the date of last follow-up for alive patients. Progression-
free survival (PFS) was defined as the time from the date of
treatment start to the date of disease progression, or the date
of death for patients that diedwithout progression, or the date
of last follow-up for patients alive and without progression
at the end of the study. OS and PFS curves were estimated
according to the Kaplan-Meier product limit method.
Statistical analyses were performedwith S-PLUS software
(S-PLUS 6.0 Professional, release 1, Insightful Corporation,
Seattle, WA, USA).
3. Results
Between October 2002 and March 2006, 8 patients were
enrolled in the prospective trial by 5 Italian institutions. The
trial was prematurely stopped, due to very slow accrual,
although the planned number of 14 patients had not been
reached. Further 10 patients, who started treatment with
weekly paclitaxel between April 2003 and November 2011,
were retrospectively included in the analysis.
One patient enrolled in the prospective trial has been
excluded from the analysis due to lack of postregistration
data. Baseline characteristics of the 17 evaluable patients,
overall and scattered by prospective versus retrospective
group, are summarized in Table 1. Median age was 64 years
(range 20–80), and most patients had ECOG performance
status 0 or 1. The majority of patients had metastatic disease
(13, 76%) and had received previous surgery. All the 7
patients enrolled in the prospective trial were pretreated with
chemotherapy for advanced disease, whilst 7 out of 10 patients
retrospectively analyzed received paclitaxel as first-line of
treatment for advanced disease. Individual characteristics of
all the treated patients are listed in Table 2.
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Table 1: Baseline characteristics.
Prospective group (𝑛 = 7) Retrospective group (𝑛 = 10) Study population (𝑛 = 17)
Gender
Males 3 (43%) 5 (50%) 8 (47%)
Females 4 (57%) 5 (50%) 9 (53%)
Age
Median (range) 63 (20–74) 68 (46–80) 64 (20–80)
ECOG performance status (3 missing data items)
0 3 (43%) 2 (29%) 5 (36%)
1 3 (43%) 5 (71%) 8 (57%)
2 1 (14%) — 1 (7%)
Stage
Locally advanced 1 (14%) 3 (30%) 4 (24%)
Metastatic 6 (86%) 7 (70%) 13 (76%)
Grading (1 missing data item)
G1 — — —
G2 3 (43%) 4 (44%) 7 (44%)
G3 4 (57%) 5 (56%) 9 (56%)
Previous surgery
Yes 5 (71%) 9 (90%) 14 (82%)
Previous chemotherapy
None — 5 (50%) 5 (29%)
Only adjuvant — 2 (20%) 2 (12%)
Advanced disease 7 (100%) 3 (30%) 10 (59%)
Table 2: Individual characteristics of the 17 patients included in the analysis.
Patient code Type ofstudy Gender Age PS Stage Grading
Previous
surgery
Previous
chemotherapy Best response PFS (months) OS (months)
1 P F 35 2 Metastatic G3 Yes Yes PD 0.9 0.9+
2 P M 64 0 Metastatic G3 No Yes PD 10.1+ 10.1+
4 P M 20 0 Metastatic G3 Yes Yes PR 1.5+ 1.5+
5 P F 50 1 Metastatic G2 Yes Yes PR 9.0 17.7
6 P F 63 0 Metastatic G2 Yes Yes PD 10.0 33.2
7 P F 67 1 Loc. adv. G3 No Yes SD 62.2+ 62.2+
8 P M 74 1 Metastatic G2 Yes Yes SD 5.5 45.9+
1001 R M 73 1 Loc. adv. G3 Yes No SD 2.7 9.6+
1002 R M 70 1 Metastatic G3 Yes Yes PD 4.6 7.1
1003 R F 66 0 Metastatic G2 Yes Yes PR 6.6 8.6+
1004 R F 75 0 Metastatic G3 Yes Yes PR 3.0 16.5
1005 R M 46 1 Metastatic n.a. Yes Yes SD 3.5 7.6+
1006 R F 61 1 Metastatic G2 Yes Yes CR 1.8 2.0
1007 R F 62 n.a. Metastatic G3 Yes No PR 2.0 20.8+
1008 R M 71 n.a. Loc. adv. G2 Yes No PD 3.8 7.3
1009 R M 80 1 Loc. adv. G3 No No SD 6.0 9.9
1010 R F 47 n.a. Metastatic G2 Yes No SD 1.8 18.6
P: prospective; R: retrospective; M: male; F: female; PS: performance status; n.a.: not available; loc. adv.: locally advanced; CR: complete response; PR:
partial response; SD: stable disease; PD: progressive disease; PFS: progression-free survival; OS: overall survival; +: patient censored without event at the last
observation.
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Figure 1: Kaplan-Meier curves of overall survival. (a) Overall survival in the whole series of patients (prospective + retrospective). Dotted
lines represent 95% confidence intervals. (b) Overall survival according to type of study: continuous line refers to patients enrolled in the
prospective study; dotted line refers to patients included in the retrospective study. (c) Overall survival according to line of treatment:
continuous line refers to patients treated with paclitaxel as first-line; dotted line refers to patients receiving paclitaxel as second-line or further
line.
Median number of paclitaxel administrations in the 17
evaluable patients was 12 (range, 4–30). Two patients received
more than 6 cycles of treatment, stopping because of disease
progression after 8 and 10 cycles, respectively. Median num-
ber of paclitaxel administrations in the 7 patients enrolled in
the prospective study was 8 (range, 6–18). Median number of
paclitaxel administrations in the 10 patients enrolled in the
retrospective study was 13.5 (range, 4–30).
Median dose intensity of paclitaxel in the 17 evalu-
able patients was 60mg/m2/week (range, 43–80). Median
dose intensity of paclitaxel in the 7 patients enrolled in
the prospective study was 60mg/m2/week (range, 44–68).
Median dose intensity of paclitaxel in the 10 patients enrolled
in the retrospective studywas 61mg/m2/week (range, 42–80).
Overall, 6 patients obtained an objective response (5
partial responses, 1 complete response). Objective response
rate was 35% (95% confidence interval 17%–59%). Of note,
five of the objective responses were obtained in patients
already pretreated with chemotherapy. Considering only the
7 patients enrolled in the prospective trial, 2 partial responses
were observed (objective response rate 29%, 95% confidence
interval 8%–64%).
After a median follow-up of 20.8 months, 14 progressions
(82%) and 8 deaths (47%) were recorded in the 17 evaluable
patients. In the prospective group, after amedian follow-up of
20.8 months, 7 progressions (100%) and 4 deaths (57%) were
recorded. In the retrospective group, after a median follow-
up of 45.9 months, 7 progressions (70%) and 4 deaths (40%)
were recorded.
Median overall survival was 18.6 months (95% confi-
dence interval (CI) 16.5–n.a.) (Figure 1(a)). In the prospective
group, median overall survival was 9.9 months (95% CI
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Figure 2: Kaplan-Meier curves of progression-free survival. (a) Progression-free survival in the whole series of patients (prospective +
retrospective). Dotted lines represent 95% confidence intervals. (b) Progression-free survival according to type of study: continuous line
refers to patients enrolled in the prospective study; dotted line refers to patients included in the retrospective study. (c) Progression-free
survival according to line of treatment: continuous line refers to patients treated with paclitaxel as first-line; dotted line refers to patients
receiving paclitaxel as second-line or further line.
7.3–n.a.), whilst, in the retrospective group, median overall
survival was 33.2 months (95% CI 16.5–n.a.) (Figure 1(b)).
In patients receiving experimental treatment as first-line,
median overall survival was not reached (95% CI 16.5–
n.a.), whilst, in patients receiving experimental treatment as
second-line or further line, median overall survival was 17.7
months (95% CI 9.9–n.a.) (Figure 1(c)).
Median progression-free survival was 4.6 months (95%
confidence interval (CI) 2.7–10.0) (Figure 2(a)). In the
prospective group, median progression-free survival was 3.5
months (95% CI 1.8–n.a.), whilst, in the retrospective group,
median progression-free survival was 5.5 months (95% CI
3.0–n.a.) (Figure 2(b)). In patients receiving experimental
treatment as first-line, median progression-free survival was
5.1 months (95% CI 3.0–n.a.), whilst, in patients receiv-
ing experimental treatment as second-line or further line,
median progression-free survival was 3.6 months (95% CI
1.8–n.a.) (Figure 2(c)).
Mild or moderate anemia was reported during treatment
in ten patients (59%), grade 1 in 9 patients and grade 2
in 1 patient. Any grade neutropenia was reported in 4
patients (24%), grade 3-4 neutropenia was reported in 2
patients, and there was no case of febrile neutropenia. Any
grade thrombocytopenia was reported in 5 patients (29%),
grade 3-4 thrombocytopenia was reported in 2 patients, and
there were no relevant bleeding episodes. Mild or moderate
asthenia was reported in 6 patients (35%), mild or moderate
skin toxicity in 3 patients (18%), grade 1-2 diarrhea in 3
patients (18%), grade 1 constipation in 3 patients (18%), and
grade 1-2 nausea or vomiting in 2 patients (12%). Neuropathy
was reported in 5 patients (grade 3 in 1, grade 2 in 1, and grade
1 in 3 patients). No severe organ toxicities were described.
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Table 3: Main characteristics and results obtained in the studies with paclitaxel in patients with advanced angiosarcoma.
Author, year [ref] Type of study Paclitaxel dose andschedule
Period of
treatment
Number of
patients
Response rate
(%)
PFS
(median)
OS
(median)
Fata et al., 1999 [20] Retrospective
250mg/m2 continuous
infusion for 24 h every 3
weeks or 175mg/m2
every 3 weeks or
90mg/m2 weekly
1992–1998 9 89 TTP 5months n.a.
Schlemmer et al.,
2008 [21] Retrospective
135–175mg/m2 every 3
weeks (𝑛 = 21) or
75–100mg/m2 weekly
(𝑛 = 11)
1996–2005 32 62 TTP 7.6months n.a.
Penel et al., 2008
[22] Prospective
80mg/m2 on days 1, 8,
and 15, every 4 weeks 2005–2006
30
(assessable
27)
18-19 TTP 4months 8 months
Penel et al., 2012 [9] Retrospective Weekly schedule 1996–2009 47 45 TTP 5.6months
13.1
months
Italiano et al., 2012
[23] Retrospective
80mg/m2 on days 1, 8,
and 15, every 4 weeks 1990–2010 75 53 5.8 months
10.3
months
Ray-Coquard et al.,
2015 [24] Prospective
Control arm: paclitaxel
90mg/m2 on days 1, 8,
and 15, every 4 weeks,
for 6 cycles
2010–2013 26
PFS: 6.8mo
Progression-
free rate at 6
months: 57%
Overall
survival at
1 year: 55%
Experimental arm: same
as control arm +
bevacizumab 10 mg/kg
on days 1, 8, and 15
followed by maintenance
therapy 15mg/kg/3 wks
until
intolerance/progression
2010–2013 26
PFS: 6.9mo
Progression-
free rate at 6
months:
57%
Overall
survival at
1 year: 58%
Our study Prospective +retrospective
80mg/m2 on days 1, 8,
and 15, every 4 weeks
Prospective:
2002–2006
Retrospective:
2003–2011
18 (17
evaluable) 35 4.6 months
18.6
months
PFS: progression-free survival; OS: overall survival; TTP: time-to-progression; n.a.: not available.
4. Discussion
In recent years, after the start of our study, several experiences
with paclitaxel in patients with advanced or metastatic
angiosarcoma have been published [20–23]. Table 3 reports
the main characteristics and results obtained in these studies
and in our series. The EORTC soft tissue and bone sarcoma
group published a retrospective study about the use of
paclitaxel in 32 patients [21]. Only 11 patients of this series
received a weekly schedule of paclitaxel; the others were
treatedwith the classical, every-3-week schedule. In thewhole
series, response rate was 62% and median progression-free
survival was 7.6 months; however many of the patients were
not pretreated with chemotherapy. These results prompted
the authors to define paclitaxel as active agent, warranting
prospective trials in this setting. Similarly, weekly paclitaxel
was associated with promising efficacy in a retrospective
analysis of patients treated between 1996 and 2009 in the
French Sarcoma Group [23].
In a prospective phase II trial, 30 patients were treated
with weekly paclitaxel, at the same schedule tested in our
study. In that series of patients (11 pretreated with chemother-
apy and 19 not pretreated), weekly paclitaxel produced 18%
response rate, amedian time-to-progression of 4months, and
a median overall survival of 8 months. Similar to our series,
results were considered encouraging also in the subgroup
of patients who had already failed previous chemotherapy,
with similar progression-free survival compared to thosewho
were treatment na¨ıve.
Recently, a randomized phase II trial testing the addi-
tion of bevacizumab to weekly paclitaxel in patients with
advanced or metastatic angiosarcoma was presented [24].
In that trial, patients assigned to control arm received
paclitaxel 90mg/m2 at days 1, 8, and 15 every 4 weeks, and
patients assigned to experimental arm received the same
schedule with the addition of bevacizumab. Unfortunately,
the addition of the antiangiogenic monoclonal antibody was
not associated with any benefit in PFS nor in overall survival.
The retrospective fraction of this study did not allow
us to describe exhaustively the adverse events related
to chemotherapy. However no important toxicities were
reported. There were no cases of febrile neutropenia and
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no relevant bleeding episodes, whilst grade 3-4 neutropenia
was reported in 2 cases and only 1 patient exhibited grade
3 neuropathy. In conclusion, our experience confirms that
weekly paclitaxel is well tolerated and active in patients with
advanced andmetastatic angiosarcomas, even though, in our
experience, duration of response was quite short. Further
studies of this agent are warranted, also in combination
with other drugs. An interesting schedule with taxanes and
doxorubicin, an active combination in other tumors, may be
amajor issue, particularly in neoadjuvant setting, whereas the
combination of anthracycline plus ifosfamide can be difficult
to administer in many angiosarcoma patients due to the age
and clinical conditions.
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